Table: Kaken Pharmaceutical -2025/26 group results

KAKEN PHARMACEUTICAL

13/05/2026 07:34

May 13 (Reuters)- 
          Kaken Pharmaceutical Co Ltd 
          CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)
                 Year ended      Year ended       Year to       NEXT   
              Mar 31, 2026    Mar 31, 2025   Mar 31, 2027     YEAR     
                 LATEST         YEAR-AGO        COMPANY      COMPANY   
                 RESULTS         RESULTS       FORECAST    H1 FORECAST 
  Sales           76.87           94.04          89.90                 
               (-18.3 pct)     (+30.5 pct)    (+17.0 pct)              
  Operating   loss 899 mln        21.03           7.90                 
                              (+121.1 pct)                             
  Recurring   loss 206 mln        21.28           8.60                 
                              (+113.8 pct)                             
  Net
  Net              2.14           13.95           6.50                 
               (-84.6 pct)     (+73.8 pct)   (+203.1 pct)              
  EPS           56.57 yen      365.42 yen     171.65 yen               
  Ann Div      190.00 yen      190.00 yen     190.00 yen               
  -Q2 Div       95.00 yen      115.00 yen      95.00 yen               
  -Q4 Div       95.00 yen       75.00 yen      95.00 yen               
  
  NOTE - Kaken Pharmaceutical Co Ltd.
  *Second Net profit row denotes profit attributable to owners ofthe parent 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4521.T